Literature DB >> 33468143

Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies.

Philippe Merviel1, Pandora James2, Sarah Bouée2, Mathilde Le Guillou2, Camille Rince2, Charlotte Nachtergaele3, Véronique Kerlan3.   

Abstract

Polycystic ovary syndrome (PCOS) is marked in 30 to 40% by insulin resistance and hyperandrogenism. Myo-inositol (MI) increases insulin sensitivity, decreases hyperandrogenism and improves the menstrual cycle. Its effect during assisted reproductive technologies (ART) has been studied by many authors. We conducted a review of the literature on the impact of MI administration in PCOS women in assisted reproductive technologies. Myo-inositol is effective in normalizing ovarian function, improving oocyte and embryo quality in PCOS, however further evaluations by large multicentre randomized controlled trials are needed to assess the clinical pregnancy and live birth rates in ART.

Entities:  

Keywords:  Embryo quality; In vitro fertilization; Intracytoplasmic sperm injection (IVF-ICSI); Myo-inositol; Polycystic ovary syndrome (PCOS); Pregnancy

Mesh：

Substances：

Year:  2021        PMID： 33468143      PMCID： PMC7816413          DOI： 10.1186/s12978-021-01073-3

Source DB:  PubMed          Journal:  Reprod Health        ISSN： 1742-4755            Impact factor:   3.223


  31 in total

1.  The D-chiro-inositol paradox in the ovary.

Authors:  Gianfranco Carlomagno; Vittorio Unfer; Scott Roseff
Journal:  Fertil Steril       Date:  2011-06-08       Impact factor: 7.329

2.  Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.

Authors:  V Unfer; G Carlomagno; P Rizzo; E Raffone; S Roseff
Journal:  Eur Rev Med Pharmacol Sci       Date:  2011-04       Impact factor: 3.507

3.  The effect of myo-inositol/di-chiro-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI: A systematic review and meta-analysis.

Authors:  Priya Bhide; Jyotsna Pundir; Anil Gudi; Amit Shah; Roy Homburg; Ganesh Acharya
Journal:  Acta Obstet Gynecol Scand       Date:  2019-05-20       Impact factor: 3.636

4.  The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen.

Authors:  Giuseppe Morgante; Raoul Orvieto; Alessandra Di Sabatino; Maria C Musacchio; Vincenzo De Leo
Journal:  Fertil Steril       Date:  2011-02-05       Impact factor: 7.329

5.  The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial.

Authors:  Azadeh Akbari Sene; Azam Tabatabaie; Hossein Nikniaz; Ahad Alizadeh; Kourosh Sheibani; Mona Mortezapour Alisaraie; Maryam Tabatabaie; Mahnaz Ashrafi; Fatemehsadat Amjadi
Journal:  Arch Gynecol Obstet       Date:  2019-03-27       Impact factor: 2.344

6.  The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial.

Authors:  Sandra Colazingari; Mariangela Treglia; Robert Najjar; Arturo Bevilacqua
Journal:  Arch Gynecol Obstet       Date:  2013-05-25       Impact factor: 2.344

7.  Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.

Authors:  P G Artini; O M Di Berardino; F Papini; A D Genazzani; G Simi; M Ruggiero; V Cela
Journal:  Gynecol Endocrinol       Date:  2013-01-22       Impact factor: 2.260

8.  Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.

Authors:  Enrico Papaleo; Vittorio Unfer; Jean-Patrice Baillargeon; Francesco Fusi; Francesca Occhi; Lucia De Santis
Journal:  Fertil Steril       Date:  2008-05-07       Impact factor: 7.329

9.  Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.

Authors:  Martino Maria Zacchè; Luigi Caputo; Susanna Filippis; Gabrio Zacchè; Moreno Dindelli; Augusto Ferrari
Journal:  Gynecol Endocrinol       Date:  2009-08       Impact factor: 2.260

10.  Prospective Randomized Study on the Influence of Myoinositol in PCOS Women Undergoing IVF in the Improvement of Oocyte Quality, Fertilization Rate, and Embryo Quality.

Authors:  Bernd Lesoine; Pedro-Antonio Regidor
Journal:  Int J Endocrinol       Date:  2016-08-22       Impact factor: 3.257
View more
  4 in total

1.  Quantification of Myoinositol in Serum by Electrochemical Detection with an Unmodified Screen-Printed Carbon Electrode.

Authors:  Xinrui Jin; Yuanqing Zhao; Xiujuan Gu; Min Zhong; Xin Kong; Guangrong Li; Gang Tian; Jinbo Liu
Journal:  J Anal Methods Chem       Date:  2022-03-29       Impact factor: 2.594

Review 2.  D-Pinitol-Active Natural Product from Carob with Notable Insulin Regulation.

Authors:  Abdullatif Azab
Journal:  Nutrients       Date:  2022-03-30       Impact factor: 5.717

3.  Therapeutic effects of aqueous extract of bioactive active component of Ageratum conyzoides on the ovarian-uterine and hypophysis-gonadal axis in rat with polycystic ovary syndrome: Histomorphometric evaluation and biochemical assessment.

Authors:  Sunday Aderemi Adelakun; Victor Okoliko Ukwenya; Akwu Bala Peter; Adewale Jacob Siyanbade; Comfort Oluwakorede Akinwumiju
Journal:  Metabol Open       Date:  2022-07-20

Review 4.  Insulin signaling as a therapeutic mechanism of lithium in bipolar disorder.

Authors:  Iain H Campbell; Harry Campbell; Daniel J Smith
Journal:  Transl Psychiatry       Date:  2022-08-29       Impact factor: 7.989
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.